Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.
- This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.
- Then, a radionuclide held tightly by Perspective’s proprietary chelator attached to an Adma group is administered.
- The research conducted at Stony Brook University refines the understanding of the potential of the proprietary CB7-Adma pre-targeting platform for image-guided radionuclide therapy for oncology.
- The technology was first described by Stony Brook University researchers, Jacob L. Houghton, Ph.D. and Vilma I.J.